Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2026

Schedule of Disaggregated Research and Development Expenses and Segment Net Loss

In addition to the significant expense categories included on the Company's consolidated statements of operations, refer below for disaggregated amounts that comprise research and development expenses and the segment net loss (in thousands):


	For the three months ended March 31,
	2026			2025
Operating expenses:
Research and development operating costs expenses excluding non-cash stock-based compensation:
Primary program research and development expenses (a)	$	15,987		$	14,739
Other research and development expenses:
Payroll and benefits		3,235			2,889
Occupancy and other overhead and operating costs		635			626
Total other research and development expenses		3,870			3,515
Research and development operating expenses excluding non-cash stock-based compensation:		19,857			18,254
General and administrative expense excluding non-cash stock-based compensation		8,381			7,179
Other segment income (expense), net (b)		9,046			1,206
Segment net loss	$	(37,284	)	$	(26,639	)

Primary program research and development expenses are comprised primarily of costs paid to third parties for clinical trials and product development manufacturing, nonclinical, regulatory, and quality assurance activities, and the portion of related research and development expenses incurred by our collaborators and third-party service providers, including contract research and manufacturing organizations that we are obligated to reimburse.

Other segment income (expense), net includes interest income, interest expense, foreign currency exchange gain or loss, depreciation and amortization, non-cash stock-based compensation, loss on extinguishment of debt and tax credit income.